Advertisement
News
Subscribe to MDT Magazine News

CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires

March 8, 2011 6:33 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, March 8, 2011 /- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH ) announced today that it is making available to its common stockholders and Series 2 Class B common stockholders a "Stockholder Questionnaire," which the Company hopes will assist it in obtaining...

TOPICS:

Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies

March 8, 2011 6:30 am | by U.S. Food & Drug Administration | Comments

New Warning about serious heart, kidney, or breathing problems which can be fatal.

TOPICS:

Amicus will resume studies on Pompe therapy

March 8, 2011 5:45 am | by The Associated Press | Comments

Amicus Therapeutics will resume studies on a treatment for the genetic disorder Pompe disease in the next few months, the company said Tuesday.The company said the Food and Drug Administration removed a clinical hold on testing of the therapy, and Amicus and regulators reached an agreement on...

Advertisement

Genetic test makers defend technology before FDA

March 8, 2011 4:45 am | by MATTHEW PERRONE - AP Health Writer - Associated Press | Comments

Genetic test makers are defending their fledgling industry and arguing the benefits of marketing their disease-predicting kits directly to consumers before regulators from the Food and Drug Administration.The two-day meeting will shape the regulation of technology that has attracted millions of...

Genzyme CEO Termeer may net $200M payout

March 8, 2011 4:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Genzyme Corp. CEO Henri Termeer could get more than $200 million from the sale of his company to French drugmaker Sanofi-aventis SA, according to a U.S. regulatory filing on Monday.

Heraeus to Launch Venus® Bulk Fill Syringes

March 8, 2011 4:35 am | by Bio-Medicine.Org | Comments

SOUTH BEND, Ind., March 8, 2011 /- Heraeus Kulzer, LLC, the leader in advancing dental esthetics and overall dental wellbeing, announced today that as a member of the Venus brand of low stress composites, Venus® Bulk Fill will now be available in syringes this March. The precise...

TOPICS:

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11

March 8, 2011 4:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 8, 2011 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today announced it will report fourth quarter and full year 2010 financial results before the NASDAQ Global Select Market opens on Friday, March 11, 2011. That same morning, Jack Lief, Arena's President and Chief...

TOPICS:

Vermillion Announces Presentation of Positive Ovarian Biomarker Data for Next Generation Test

March 8, 2011 4:34 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, March 8, 2011 /- (Nasdaq: VRML ) –Vermillion, a molecular diagnostics company, today announced the presentation of positive preliminary data from its collaboration with Johns Hopkins University School of Medicine to identify biomarkers that improve on the specificity...

TOPICS:
Advertisement

New Mexico Software Enhances Technology Staff to Support Anticipated Sales Growth

March 8, 2011 4:33 am | by Bio-Medicine.Org | Comments

ALBUQUERQUE, N.M., March 8, 2011 /- New Mexico Software, Inc. (OTC Bulletin Board: NMXC ) announced today enhancements to its technology staff in response to anticipated demand for the company's strong lineup of technology products that support medical IT services and solutions. The...

TOPICS:

Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference

March 8, 2011 3:36 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J., March 8, 2011 /- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), an emerging specialty pharmaceutical company, today announced that David Stack, president and chief executive officer, is scheduled to present at the Barclays Capital 2011 Global Healthcare Conference on...

TOPICS:

Aethlon Medical Receives FDA Approval to Export its Hemopurifier® to India

March 8, 2011 3:36 am | by Bio-Medicine.Org | Comments

SAN DIEGO, March 8, 2011 /- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD ), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Aethlon's request to export its...

TOPICS:

Codexis Names Jacques Beaudry-Losique VP Corporate Development & Strategy

March 8, 2011 3:35 am | by Bio-Medicine.Org | Comments

REDWOOD CITY, Calif., March 8, 2011 /- Codexis, Inc. (Nasdaq: CDXS ) today announced that Jacques Beaudry-Losique has joined the company as Vice President, Corporate Development and Strategy.  Mr. Beaudry-Losique joins Codexis from the U.S. Department of Energy, and will be...

TOPICS:

RBC Life Sciences Reports Sales and Earnings Growth in 2010

March 8, 2011 3:35 am | by Bio-Medicine.Org | Comments

IRVING, Texas, March 8, 2011 /- (RBC Life Sciences: OTC Bulletin Board: RBCL ) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported a 13% increase in consolidated net sales to $28.2 million for the year...

TOPICS:

Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer

March 8, 2011 3:33 am | by Bio-Medicine.Org | Comments

VERNON HILLS, Ill., March 8, 2011 /- Genus Oncology, LLC, a clinical-stage company focused on commercializing novel drugs for treatment of cancer, announced it has received an Orphan Drug Designation from the FDA's Office of Orphan Products Development for its Mucin 1 (MUC1) targeting...

TOPICS:

Japan Terumo to buy US medical firm for $2.6B

March 8, 2011 2:45 am | by The Associated Press | Comments

Japanese medical-equipment manufacturer Terumo Corp. says it will buy U.S. company CaridianBCT for $2.63 billion.Terumo said it plans to close the deal by May of this year.The Japanese firm said the deal, announced Monday, will make it the largest company by sales in the global blood...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading